Background: Certainly, there is a demand for stronger recognition of how nanoparticles can move through the cell membrane. Prostate cancer is one of the forcing sources of cancerrelevant deaths among men. Aim of the Work: The current research studied the power of prostate cancer cells to uptake a ternary nanocomposite TNT/CuFe 2 O 4 /Zn-Fe mixed metal oxides (MMO). Methodology: The nanocomposite was synthesized by a chemical method and characterized by a High-resolution transmission electron microscope, Field emission scanning electron microscope, X-ray diffraction, Fourier transmission infra-red, X-ray photoelectron spectroscopy, dynamic light scattering. Besides, it was implemented as an inorganic anticancer agent versus Prostate cancer PC-3 cells. Results: The results revealed cellular uptake validity, cell viability reduction, ultra-structures alterations, morphological changes and membrane damage of PC-3 cells. Conclusion: The prepared ternary nanocomposite was highly uptake by PC-3 cells and possessed cytotoxicity that was dose and time-dependent. To conclude, the study offered the potential of the investigated ternary nanocomposite as a promising prostate anticancer agent.
BackgroundInvestigations have indicated that 25% of men are diagnosed with prostate cancer (PCa). 1 The clinical diagnostic approach is testing the prostate-specific antigen (PSA) level, where a concentration ˃ 4 ng/mL is considered a risk of biopsy. 2 The routine diagnostic technique is the digital rectal examination, and Multi-parametric-magnetic resonance imaging allows the potential diagnosis of PCa. 3 The distinct five stages of PCa are (zero) I, II, III, and IV, 4 and most cases of prostate cancer metastasis develop in the lymph nodes and the bones. 5 Choice of the treatment procedure, whatever surgery, radiation, hormone, Cryo-therapy, Vaccine, and Bone-directed treatment depends on the clinical stage, the age, and the general health of the individual. 6 The potential complications of the mentioned approaches are serious to consider. 7 The prostate size is the fundamental limitation of surgery, and 5 to 20% of cases suffer from stress incontinence after radical prostatectomy. Hormonal therapy leads to loss of libido, bone, and muscle mass. 8 Further, 30 to 50% experience erectile dysfunction after radiation therapy, 9 and urinary retention, urgency, and frequency are more common in Brachytherapy.